CA2366723C - Fatty acid-anticancer conjugates and uses thereof - Google Patents

Fatty acid-anticancer conjugates and uses thereof Download PDF

Info

Publication number
CA2366723C
CA2366723C CA2366723A CA2366723A CA2366723C CA 2366723 C CA2366723 C CA 2366723C CA 2366723 A CA2366723 A CA 2366723A CA 2366723 A CA2366723 A CA 2366723A CA 2366723 C CA2366723 C CA 2366723C
Authority
CA
Canada
Prior art keywords
fatty acid
anticancer compound
conjugate
taxane
mtd
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2366723A
Other languages
English (en)
French (fr)
Other versions
CA2366723A1 (en
Inventor
Nigel L. Webb
Matthews O. Bradley
Forrest Anthony
Mark Fisher
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
American Regent Inc
Original Assignee
Luitpold Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/265,307 external-priority patent/US7235583B1/en
Application filed by Luitpold Pharmaceuticals Inc filed Critical Luitpold Pharmaceuticals Inc
Publication of CA2366723A1 publication Critical patent/CA2366723A1/en
Application granted granted Critical
Publication of CA2366723C publication Critical patent/CA2366723C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA2366723A 1999-03-09 2000-03-09 Fatty acid-anticancer conjugates and uses thereof Expired - Fee Related CA2366723C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US09/265,307 1999-03-09
US09/265,307 US7235583B1 (en) 1999-03-09 1999-03-09 Fatty acid-anticancer conjugates and uses thereof
US18615200P 2000-03-01 2000-03-01
US60/186,152 2000-03-01
PCT/US2000/006160 WO2000053231A2 (en) 1999-03-09 2000-03-09 Fatty acid-anticancer conjugates and uses thereof

Publications (2)

Publication Number Publication Date
CA2366723A1 CA2366723A1 (en) 2000-09-14
CA2366723C true CA2366723C (en) 2011-08-02

Family

ID=26881822

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2366723A Expired - Fee Related CA2366723C (en) 1999-03-09 2000-03-09 Fatty acid-anticancer conjugates and uses thereof

Country Status (10)

Country Link
EP (1) EP1163011A2 (cs)
JP (1) JP2002538224A (cs)
KR (1) KR20020000147A (cs)
CN (1) CN1377282A (cs)
AU (1) AU3733300A (cs)
CA (1) CA2366723C (cs)
CZ (1) CZ20013123A3 (cs)
HK (1) HK1040486A1 (cs)
RU (1) RU2001127313A (cs)
WO (1) WO2000053231A2 (cs)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994392A (en) * 1988-02-26 1999-11-30 Neuromedica, Inc. Antipsychotic prodrugs comprising an antipsychotic agent coupled to an unsaturated fatty acid
US7816398B2 (en) * 2001-03-23 2010-10-19 Luitpold Pharmaceuticals, Inc. Fatty alcohol drug conjugates
JP2005500988A (ja) * 2001-03-23 2005-01-13 ルイトポルド・ファーマシューティカルズ・インコーポレーテッド 脂肪族アミン薬物複合体
US7169752B2 (en) 2003-09-30 2007-01-30 New River Pharmaceuticals Inc. Compounds and compositions for prevention of overdose of oxycodone
CN100341589C (zh) 2002-05-24 2007-10-10 血管技术国际股份公司 用于涂覆医用植入物的组合物和方法
CA2529125A1 (en) 2003-06-19 2004-12-23 Yeda Research & Development Co. Ltd. Antimicrobial and anticancer lipopeptides
EP1703904B1 (en) * 2003-10-30 2013-02-13 The Research Foundation of the State University of New York Taxoid-fatty acid conjugates and pharmaceutical compositions thereof
JP4929158B2 (ja) * 2005-03-14 2012-05-09 株式会社大塚製薬工場 難水溶性薬物を含有する医薬組成物
KR100753112B1 (ko) * 2007-02-26 2007-08-29 (주)고려다이나믹스 카드 발권 시스템
AU2013288738A1 (en) * 2012-07-10 2015-01-29 Baseclick Gmbh Anandamide-modified nucleic acid molecules
CN117088935A (zh) * 2022-05-20 2023-11-21 上海维洱生物医药科技有限公司 一种雷公藤甲素木蜡酸酯及其脂质体与制备方法
KR20230174082A (ko) * 2022-06-20 2023-12-27 (주) 바이오인프라생명과학 약물을 전달하기 위한 초음파 감응형 약물전달체를 생성하는 방법 및 이를 이용한 초음파 감응형 약물전달체
CN116676355B (zh) * 2023-08-03 2023-10-24 成都第一制药有限公司 一种催化合成山莨菪碱的方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5925327A (ja) * 1982-07-31 1984-02-09 Hidematsu Hirai 抗腫瘍性複合体の製造方法
AU3243393A (en) * 1991-12-10 1993-07-19 Rush - Presbyterian - St. Luke's Medical Center Methods and compositions for reducing multi-drug resistance
US5925669A (en) * 1994-03-22 1999-07-20 Molecular/Structural Bio Technologies, Inc. Carrier compositions for anti-neoplastic drugs
US5580899A (en) * 1995-01-09 1996-12-03 The Liposome Company, Inc. Hydrophobic taxane derivatives
JP4172726B2 (ja) * 1996-05-22 2008-10-29 ルイトポルド・ファーマシューティカルズ・インコーポレーテッド シス―ドコサヘキサエン酸とドセタキセルとの共有複合体を含有する製剤
US5795909A (en) * 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
US5919815A (en) * 1996-05-22 1999-07-06 Neuromedica, Inc. Taxane compounds and compositions
US6136988A (en) * 1998-04-10 2000-10-24 Hauser, Inc. 7-hexanoyltaxol and methods for preparing the same

Also Published As

Publication number Publication date
RU2001127313A (ru) 2003-09-20
CZ20013123A3 (cs) 2002-03-13
AU3733300A (en) 2000-09-28
CN1377282A (zh) 2002-10-30
WO2000053231A2 (en) 2000-09-14
JP2002538224A (ja) 2002-11-12
HK1040486A1 (zh) 2002-06-14
KR20020000147A (ko) 2002-01-04
CA2366723A1 (en) 2000-09-14
WO2000053231A3 (en) 2001-10-04
EP1163011A2 (en) 2001-12-19

Similar Documents

Publication Publication Date Title
US7816398B2 (en) Fatty alcohol drug conjugates
US8552054B2 (en) Fatty amine drug conjugates
CA2366723C (en) Fatty acid-anticancer conjugates and uses thereof
US6576636B2 (en) Method of treating a liver disorder with fatty acid-antiviral agent conjugates
AU725759B2 (en) DHA-pharmaceutical agent conjugates
AU720704B2 (en) Conjugates of cis-docosahexaenoic acid and paclitaxel
JP5421340B2 (ja) 癌治療のためのアジア酸またはアジアチコサイドの使用。
US20080125380A1 (en) Fatty acid-anticancer conjugates and uses thereof
WO1997044336A9 (en) Conjugates of cis-docosahexaenoic acid and paclitaxel
CA2408562A1 (en) Dehydroascorbic acid formulations and uses thereof
WO2000067802A1 (en) Fatty acid-n-substituted indol-3-glyoxyl-amide compositions and uses thereof
WO2014199239A2 (en) Methods relating to the use of remote ischemic conditioning
AU2008203341A1 (en) Fatty acid-anticancer conjugates and uses thereof
AU2005201503A1 (en) Fatty acid-anticancer conjugates and uses thereof
EP2473506A2 (en) Compounds and compositions for treating cancer
AU1632801A (en) DHA-pharmaceutical agent conjugates

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20170309